Literature DB >> 15292887

The treatment of cerebral palsy: What we know, what we don't know.

Murray Goldstein1.   

Abstract

The treatment of cerebral palsy is directed at repair of the injured brain and at the management of the impairments and disabilities resulting from developmental brain injury. Currently, there are no clinically meaningful interventions that can successfully repair existing damage to the brain areas that control muscle coordination and movement. However, several interventions are available to diminish the degree of impairment (eg, muscle spasticity) and to increase participation in activities of daily living. Data on treatment compatible with evidence-based medicine are now being collected. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292887     DOI: 10.1016/j.jpeds.2004.05.022

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  Examining mobility, independence, motor function, participation, and parental stress in a school-aged Turkish cerebral palsy population: a cross-sectional study.

Authors:  İpek Alemdaroğlu-Gürbüz; Arzu Burcu Karakuş
Journal:  Neurol Sci       Date:  2019-07-01       Impact factor: 3.307

2.  Efficacy of Selective Dorsal Rhizotomy and Intrathecal Baclofen Pump in the Management of Spasticity.

Authors:  Pramath Kakodkar; Hidy Girgis; Perla Nabhan; Sharini Sam Chee; Albert Tu
Journal:  Adv Tech Stand Neurosurg       Date:  2022

Review 3.  Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.

Authors:  Marissa Barlaan Lukban; Raymond L Rosales; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

4.  Multilevel botulinum toxin type a as a treatment for spasticity in children with cerebral palsy: a retrospective study.

Authors:  Ece Unlu; Alev Cevikol; Burcu Bal; Emel Gonen; Ozlem Celik; Gulşen Kose
Journal:  Clinics (Sao Paulo)       Date:  2010-06       Impact factor: 2.365

5.  [Quality assurance in the orthopaedic management of neuromuscular diseases].

Authors:  W M Strobl
Journal:  Orthopade       Date:  2010-01       Impact factor: 1.087

Review 6.  Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy.

Authors:  Makoto Nabetani; Haruo Shintaku; Takashi Hamazaki
Journal:  Pediatr Res       Date:  2017-11-08       Impact factor: 3.756

7.  Differentiation between non-neural and neural contributors to ankle joint stiffness in cerebral palsy.

Authors:  Karin L de Gooijer-van de Groep; Erwin de Vlugt; Jurriaan H de Groot; Hélène C M van der Heijden-Maessen; Dennis H M Wielheesen; Rietje M S van Wijlen-Hempel; J Hans Arendzen; Carel G M Meskers
Journal:  J Neuroeng Rehabil       Date:  2013-07-23       Impact factor: 4.262

8.  Preclinical assessment of thrombin-preconditioned human Wharton's jelly-derived mesenchymal stem cells for neonatal hypoxic-ischaemic brain injury.

Authors:  Jung-Ho Noh; Ji-Seong Jeong; Sang-Jin Park; Kyung Jin Jung; Byoung-Seok Lee; Woo-Jin Kim; Ji-Seok Han; Min-Kyung Cho; Dong Kyung Sung; So Yoon Ahn; Yun Sil Chang; Hwa-Young Son; Eun Ju Jeong
Journal:  J Cell Mol Med       Date:  2021-10-15       Impact factor: 5.310

9.  Therapeutic potential of umbilical cord mesenchymal stromal cells transplantation for cerebral palsy: a case report.

Authors:  Liming Wang; Haijie Ji; Jianjun Zhou; Jiang Xie; Zhanqiang Zhong; Ming Li; Wen Bai; Na Li; Zijia Zhang; Xuejun Wang; Delin Zhu; Yongjun Liu; Mingyuan Wu
Journal:  Case Rep Transplant       Date:  2013-03-03

10.  The Effect of Umbilical Cord-derived Mesenchymal Stem Cell Transplantation in a Patient with Cerebral Palsy: A Case Report.

Authors:  Sibel Çağlar Okur; Sinan Erdoğan; Cansu Subaşı Demir; Gülşen Günel; Erdal Karaöz
Journal:  Int J Stem Cells       Date:  2018-05-30       Impact factor: 2.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.